Astellas Licenses RIKEN’s aAVC Cell Therapy Technology for US$9.4 M Upfront

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 9 (Table of Contents)

Published: 6 Sep-2019

DOI: 10.3833/pdr.v2019.i9.2455     ISSN: 1756-7874

Section: Licensing



Less than a year after it acquired Potenza Therapeutics to break into the immuno-oncology market, Astellas Pharma has now licensed the global rights to RIKEN’s artificial adjuvant vector cell (aAVC) technology for selected cancer antigen targets...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details